Does boceprevir really increase the risk of skin eruptions during antihepatitis C treatment?
This article is protected by copyright. All rights reserved. (Source: British Journal of Dermatology)
Source: British Journal of Dermatology - August 1, 2015 Category: Dermatology Authors: R. Carrascosa, M. Llamas‐Velasco, A. Montes‐Torres, J. Sánchez‐Pérez Tags: Letter to the Editor Source Type: research
Favourable SVR12 rates with boceprevir or telaprevir triple therapy in HIV÷ HCV coinfected patients.
CONCLUSION: In HIV÷ HCV coinfected patients, boceprevir or telaprevir triple therapy was well tolerated and resulted in favourable SVR12 rates comparable with previous publications concerning HCV mono-infected patients.
PMID: 26314715 [PubMed - in process] (Source: The Netherlands Journal of Medicine)
Source: The Netherlands Journal of Medicine - August 1, 2015 Category: Journals (General) Authors: Arends JE, van der Meer JT, Posthouwer D, Kortmann W, Brinkman K, van Assen S, Smit C, van der Valk M, van der Ende M, Schinkel J, Reiss P, Richter C, Hoepelman AI Tags: Neth J Med Source Type: research
Ombitasvir/Paritaprevir/r, Dasabuvir and Ribavirin for Cirrhotic HCV Patients with Thrombocytopenia and Hypoalbuminemia
ConclusionsThe findings of these analyses support the use of ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin in these subpopulations with cirrhosis. Genotype 1a‐infected patients with indicators of portal hypertension may benefit from a 24‐week treatment duration.This article is protected by copyright. All rights reserved. (Source: Liver International)
Source: Liver International - August 1, 2015 Category: Gastroenterology Authors: Xavier Forns, Fred Poordad, Marcos Pedrosa, Marina Berenguer, Heiner Wedemeyer, Peter Ferenci, Mitchell Shiffman, Michael W. Fried, Sandra Lovell, Roger Trinh, Juan Carlos Lopez‐Talavera, Gregory Everson Tags: Rapid Communication Source Type: research
HCV NS3 Quasispecies in Liver and Plasma and Dynamics of Telaprevir-Resistant Variants in Breakthrough Patients Assessed by UDPS: a Case Study
The Hepatitis C Virus (HCV) diversity is considered a key factors in prediction of HCV treatment response [1,2]. In fact, in the era of direct acting antiviral agents (DAAs), the new drugs can rapidly select resistant variants, leading to treatment failure [3,4]. (Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - July 29, 2015 Category: Virology Authors: Barbara Bartolini, Marina Selleri, Anna Rosa Garbuglia, Emanuela Giombini, Chiara Taibi, Raffaella Lionetti, Gianpiero D'Offizi, Maria R. Capobianchi Tags: Short Communication Source Type: research
The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients
Summary
Triple therapy using boceprevir or telaprevir remains the reference treatment for genotype 1 chronic hepatitis C in countries where new interferon‐free regimens have not yet become available. Antiviral treatment is highly required in cirrhotic patients, but they represent a difficult‐to‐treat population. We aimed to develop a simple algorithm for the prediction of sustained viral response (SVR) in cirrhotic patients treated with triple therapy. A total of 484 cirrhotic patients from the ANRS CO20 CUPIC cohort treated with triple therapy were randomly distributed into derivation and validation sets. A total of...
Source: Journal of Viral Hepatitis - July 27, 2015 Category: Infectious Diseases Authors: J. Boursier, A. Ducancelle, J. Vergniol, P. Veillon, V. Moal, C. Dufour, J.‐P. Bronowicki, D. Larrey, C. Hézode, F. Zoulim, H. Fontaine, V. Canva, T. Poynard, S. Allam, V. De Lédinghen, Tags: Original Article Source Type: research
Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice
Conclusions
Treatment failure with asunaprevir/daclatasvir may limit further treatment options. This population may represent a growing unmet medical need. (Source: Journal of Gastroenterology)
Source: Journal of Gastroenterology - July 25, 2015 Category: Gastroenterology Source Type: research
Comparative safety study on severe anemia by simeprevir versus telaprevir‐based triple therapy for chronic hepatitis C
ConclusionsPatients treated with simeprevir‐based triple therapy have a lower risk of the development of severe anemia than those treated with telaprevir. Moreover, ITPA genotype and age may be useful for individualizing treatment to reduce the risk of anemia‐related adverse effects. (Source: Journal of Gastroenterology and Hepatology)
Source: Journal of Gastroenterology and Hepatology - July 23, 2015 Category: Gastroenterology Authors: Eiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, Hideyuki Nomura, Akira Kawano, Kazuhiro Takahashi, Kazufumi Dohmen, Takeaki Satoh, Koichi Azuma, Makoto Nakamuta, Toshimasa Koyanagi, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Tags: Hepatology Source Type: research
Belgian experience with triple therapy with boceprevir and telaprevir in genotype 1 infected patients who inject drugs
No data have been reported yet on treatment outcome in persons who inject drugs (PWID) infected with hepatitis C virus treated with boceprevir or telaprevir in combination with peginterferon (Peg IFN) and ribavirin (RBV). Additionally, there are concerns about the safety of boceprevir and telaprevir in some subgroups of patients with hepatitis C (HCV). In a cohort of HCV patients infected with genotype 1 in Belgium, treatment outcome of patients infected due to IV drug use was analyzed and compared with patients who have no history of substance use. The study population consisted of 179 patients: 78 PWID and 101 controls t...
Source: Journal of Medical Virology - July 21, 2015 Category: Virology Authors: A. Arain, S. Bourgeois, C. de Galocsy, J. Henrion, P. Deltenre, F. d'Heygere, C. George, B. Bastens, L. Van Overbeke, R. Verrando, L. Bruckers, C. Mathei, F. Buntinx, H. Van Vlierberghe, S. Francque, W. Laleman, C. Moreno, F. Janssens, F. Nevens, G. Robae Tags: Research Article Source Type: research
Protease inhibitors‐based therapy induces acquired spherocytic‐like anaemia and ineffective erythropoiesis in chronic hepatitis C virus patients
ConclusionsThe bimodal pattern of anaemia in chronic HCV patients on triple therapy might be because of acquired spherocytic‐like anaemia in the early phase, followed by hyporegenerative anaemia, most likely related to the combined effects of PR and TRV or BOC on erythropoiesis. (Source: Liver International)
Source: Liver International - July 14, 2015 Category: Gastroenterology Authors: Francesca Lupo, Roberta Russo, Achille Iolascon, Donatella Ieluzzi, Angela Siciliano, Pierluigi Toniutto, Alessandro Matté, Sara Piovesan, Elena Raffetti, Francesco Turrini, Denis Dissegna, Francesco Donato, Alfredo Alberti, Valeria Zuliani, Giovanna Fat Tags: Original Article Source Type: research
Fair prices for new direct-acting antiviral agents (DAAs) to make treatment for all affordable
Until 2011, the combination of pegylated interferon (pINF) and ribavirin (RBV) for 24 or 48 weeks was the approved treatment for chronic hepatitis C (CHC). Telaprevir and boceprevir, licensed in 2011 for use in patients infected with HCV genotype 1, were the first direct-acting antiviral agents (DAAs). With combinations including these agents, higher sustained viral response (SVR) rates were achieved compared with pINF+RBV, but also higher side effects. In 2013, sofosbuvir (SOF) was approved for use in HCV-infected patients with genotypes 2 and 3 in combination with RBV, and in those with genotypes 1 and 4, in combina...
Source: Gut - July 9, 2015 Category: Gastroenterology Authors: Deuffic-Burban, S., Yazdanpanah, Y. Tags: Commentary Source Type: research
Predictive factors associated with hepatitis C antiviral therapy response.
Authors: Cavalcante LN, Lyra AC
Abstract
Hepatitis C virus (HCV) infection may lead to significant liver injury, and viral, environmental, host, immunologic and genetic factors may contribute to the differences in the disease expression and treatment response. In the early 2000s, dual therapy using a combination of pegylated interferon plus ribavirin (PR) became the standard of care for HCV treatment. In this PR era, predictive factors of therapy response related to virus and host have been identified. In 2010/2011, therapeutic regimens for HCV genotype 1 patients were modified, and the addition of NS3/4a ...
Source: World Journal of Hepatology - July 5, 2015 Category: Gastroenterology Tags: World J Hepatol Source Type: research
Severe immune thrombocytopenia after peg-interferon-alpha2a, ribavirin and telaprevir treatment completion: A case report and systematic review of literature.
Authors: Arena R, Cecinato P, Lisotti A, Buonfiglioli F, Calvanese C, Grande G, Montagnani M, Azzaroli F, Mazzella G
Abstract
Mild to moderate autoimmune thrombocytopenia (AITP) is a common finding in patients receiving interferon-based antiviral treatment, due to bone marrow suppression. Here we report the case of a patient with chronic genotype 1b hepatitis C virus (HCV) infection treated with pegylated-interferon alpha-2a, ribavirin and telaprevir for 24 wk; the patient developed severe AITP three weeks after treatment withdrawal. We performed a systematic literature search in order to review all publis...
Source: World Journal of Hepatology - July 5, 2015 Category: Gastroenterology Tags: World J Hepatol Source Type: research
Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake
ConclusionsThe introduction of PI‐based HCV treatment in HIV/HCV‐coinfected patients improved virological response rates, while treatment uptake remained low. Therefore, the introduction of PIs into the clinical routine was beneficial at the individual level, but had only a modest effect on the burden of HCV infection at the population level. (Source: HIV Medicine)
Source: HIV Medicine - July 2, 2015 Category: Infectious Diseases Authors: V Schaerer, S Haubitz, H Kovari, B Ledergerber, J Ambrosioni, M Cavassini, M Stoeckle, P Schmid, L Decosterd, M Aouri, J Böni, HF Günthard, H Furrer, KJ Metzner, J Fehr, A Rauch, Tags: Original Research Source Type: research
Real-life experience with first generation HCV protease inhibitor therapy in Germany: The prospective, non-interventional PAN cohort.
Conclusions: The efficacy and safety of BOC- and TVR-based triple therapy in this large, "real-world" cohort were largely comparable to that reported in pivotal clinical trials, although SVR rates were lower overall. Recommended futility or treatment extension rules were violated in a substantial proportion of patients with potential implications for response, adverse events and costs.
PMID: 26167694 [PubMed - as supplied by publisher] (Source: Zeitschrift fur Gastroenterologie)
Source: Zeitschrift fur Gastroenterologie - July 1, 2015 Category: Gastroenterology Authors: Mauss S, Böker K, Buggisch P, Christensen S, Hofmann WP, Schott E, Pfeiffer-Vornkahl H, Alshuth U, Hüppe D Tags: Z Gastroenterol Source Type: research
The Belgian experience with triple therapy with boceprevir and telaprevir in genotype 1 infected patients who inject drugs
ConclusionsThere are no reasons to exclude PWID from treatment with boceprevir, telaprevir and novel antiviral therapies. This article is protected by copyright. All rights reserved (Source: Journal of Medical Virology)
Source: Journal of Medical Virology - June 30, 2015 Category: Virology Authors: A Arain, S Bourgeois, C de Galocsy, J Henrion, P Deltenre, F d'Heygere, C George, B Bastens, L Van Overbeke, R Verrando, L Bruckers, C Mathei, F Buntinx, H Van Vlierberghe, S Francque, W Laleman, C Moreno, F Janssens, F Nevens, G Robaeys Tags: Research Article Source Type: research
